Clinical trial
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
NCT00153920 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00153920 |
|---|---|
| Title | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma |
| Official title | Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Massachusetts General Hospital Brigham and Women's Hospital Roswell Park Cancer Institute Emory University Memorial Sloan Kettering Cancer Center Millennium… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 66 |
| Start date | Dec 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Jun 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: